Nisenson maintains her position as supervising producer, continuing to oversee the team responsible for translating complex medical and biotech developments into patient-focused narratives. Her promotion formalizes a leadership trajectory that has already seen the agency pivot from a broad corporate client base to a singular, decade-long focus on pharma and medtech innovation.
Under her guidance, the firm is currently tracking toward an ambitious 2034 target of facilitating access to 150 life-changing medical innovations. The team has already produced content for 114 distinct therapies, bridging the gap between clinical complexity and human experience. According to Lewin, Nisenson’s background in patient journey mapping serves as the cornerstone for the company’s ongoing strategy to support Fortune 500 healthcare brands.
Comments (0)
No comments yet. Be the first!